25 XP   0   0   10

Galapagos N.V.
Buy, Hold or Sell?

Let's analyse Galapagos N.V. together

PenkeI guess you are interested in Galapagos N.V.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Galapagos N.V.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Galapagos N.V.

I send you an email if I find something interesting about Galapagos N.V..

Quick analysis of Galapagos N.V. (30 sec.)










What can you expect buying and holding a share of Galapagos N.V.? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
‚ā¨43.93
Expected worth in 1 year
‚ā¨48.95
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨5.01
Return On Investment
21.1%

For what price can you sell your share?

Current Price per Share
‚ā¨23.80
Expected price per share
‚ā¨0 - ‚ā¨26.30
How sure are you?
50%

1. Valuation of Galapagos N.V. (5 min.)




Live pricePrice per Share (EOD)

‚ā¨23.80

Intrinsic Value Per Share

‚ā¨-98.88 - ‚ā¨9.76

Total Value Per Share

‚ā¨-54.95 - ‚ā¨53.69

2. Growth of Galapagos N.V. (5 min.)




Is Galapagos N.V. growing?

Current yearPrevious yearGrowGrow %
How rich?$3.1b$2.7b$125.3m4.3%

How much money is Galapagos N.V. making?

Current yearPrevious yearGrowGrow %
Making money$74.6m-$48.5m$123.2m165.1%
Net Profit Margin23.5%-50.7%--

How much money comes from the company's main activities?

3. Financial Health of Galapagos N.V. (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#25 / 991

Most Revenue
#167 / 991

Most Profit
#25 / 991

What can you expect buying and holding a share of Galapagos N.V.? (5 min.)

Welcome investor! Galapagos N.V.'s management wants to use your money to grow the business. In return you get a share of Galapagos N.V..

What can you expect buying and holding a share of Galapagos N.V.?

First you should know what it really means to hold a share of Galapagos N.V.. And how you can make/lose money.

Speculation

The Price per Share of Galapagos N.V. is ‚ā¨23.80. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Galapagos N.V..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Galapagos N.V., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨43.93. Based on the TTM, the Book Value Change Per Share is ‚ā¨1.25 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨-0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Galapagos N.V..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps1.476.2%1.134.8%-0.74-3.1%-0.05-0.2%-0.14-0.6%
Usd Book Value Change Per Share1.626.8%1.345.6%-0.23-1.0%1.405.9%1.084.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.626.8%1.345.6%-0.23-1.0%1.405.9%1.084.6%
Usd Price Per Share31.68-36.54-46.49-84.75-73.52-
Price to Earnings Ratio5.40-37.68-2.36-10.15--7.62-
Price-to-Total Gains Ratio19.60-54.48-60.85-3,751.64-2,055.87-
Price to Book Ratio0.67-0.83-1.10-2.12-3.82-
Price-to-Total Gains Ratio19.60-54.48-60.85-3,751.64-2,055.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share25.48742
Number of shares39
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.341.40
Usd Total Gains Per Share1.341.40
Gains per Quarter (39 shares)52.3554.48
Gains per Year (39 shares)209.41217.93
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102091990218208
204194080436426
306286170654644
408388260872862
5010471035010901080
6012561244013081298
7014661453015261516
8016751662017431734
9018851871019611952
10020942080021792170

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%7.05.00.058.3%10.010.00.050.0%14.025.01.035.0%20.026.031.026.0%
Book Value Change Per Share4.00.00.0100.0%10.02.00.083.3%13.07.00.065.0%20.017.03.050.0%31.027.019.040.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.077.00.0%
Total Gains per Share4.00.00.0100.0%10.02.00.083.3%13.07.00.065.0%20.017.03.050.0%31.027.019.040.3%

Fundamentals of Galapagos N.V.

About Galapagos N.V.

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Fundamental data was last updated by Penke on 2024-05-26 00:05:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Galapagos N.V..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Galapagos N.V. earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Galapagos N.V. to the¬†Biotechnology industry mean.
  • A Net Profit Margin of 144.5%¬†means that¬†€1.45 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Galapagos N.V.:

  • The MRQ is 144.5%. The company is making a huge profit. +2
  • The TTM is 23.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ144.5%TTM23.5%+121.0%
TTM23.5%YOY-50.7%+74.2%
TTM23.5%5Y-31.6%+55.1%
5Y-31.6%10Y-69.2%+37.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ144.5%-178.5%+323.0%
TTM23.5%-223.7%+247.2%
YOY-50.7%-245.1%+194.4%
5Y-31.6%-390.8%+359.2%
10Y-69.2%-503.2%+434.0%
1.1.2. Return on Assets

Shows how efficient Galapagos N.V. is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Galapagos N.V. to the¬†Biotechnology industry mean.
  • 2.1% Return on Assets means that¬†Galapagos N.V. generated¬†€0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Galapagos N.V.:

  • The MRQ is 2.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.1%TTM1.6%+0.5%
TTM1.6%YOY-1.0%+2.5%
TTM1.6%5Y-0.2%+1.8%
5Y-0.2%10Y-1.3%+1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1%-11.6%+13.7%
TTM1.6%-11.6%+13.2%
YOY-1.0%-10.9%+9.9%
5Y-0.2%-12.9%+12.7%
10Y-1.3%-14.1%+12.8%
1.1.3. Return on Equity

Shows how efficient Galapagos N.V. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Galapagos N.V. to the¬†Biotechnology industry mean.
  • 3.1% Return on Equity means Galapagos N.V. generated €0.03¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Galapagos N.V.:

  • The MRQ is 3.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.5%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.1%TTM2.5%+0.6%
TTM2.5%YOY-1.8%+4.3%
TTM2.5%5Y-0.3%+2.8%
5Y-0.3%10Y-1.6%+1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1%-13.9%+17.0%
TTM2.5%-14.9%+17.4%
YOY-1.8%-13.5%+11.7%
5Y-0.3%-18.2%+17.9%
10Y-1.6%-19.0%+17.4%

1.2. Operating Efficiency of Galapagos N.V..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Galapagos N.V. is operating .

  • Measures how much profit Galapagos N.V. makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Galapagos N.V. to the¬†Biotechnology industry mean.
  • An Operating Margin of 0.0%¬†means the company generated €0.00 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Galapagos N.V.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.2%-0.2%
TTM0.2%YOY-52.5%+52.7%
TTM0.2%5Y-34.8%+35.0%
5Y-34.8%10Y-85.4%+50.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--344.0%+344.0%
TTM0.2%-235.7%+235.9%
YOY-52.5%-262.3%+209.8%
5Y-34.8%-383.7%+348.9%
10Y-85.4%-485.1%+399.7%
1.2.2. Operating Ratio

Measures how efficient Galapagos N.V. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Biotechnology industry mean).
  • An Operation Ratio of 1.57 means that the operating costs are €1.57 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Galapagos N.V.:

  • The MRQ is 1.571. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.024. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.571TTM1.024+0.548
TTM1.024YOY1.525-0.501
TTM1.0245Y1.631-0.607
5Y1.63110Y2.892-1.262
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5713.092-1.521
TTM1.0243.353-2.329
YOY1.5253.564-2.039
5Y1.6314.836-3.205
10Y2.8926.187-3.295

1.3. Liquidity of Galapagos N.V..

1.3. Liquidity
1.3.1. Current Ratio

Measures if Galapagos N.V. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Biotechnology industry mean).
  • A Current Ratio of 9.91¬†means the company has €9.91 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Galapagos N.V.:

  • The MRQ is 9.907. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.080. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.907TTM9.080+0.826
TTM9.080YOY8.168+0.913
TTM9.0805Y8.696+0.385
5Y8.69610Y7.562+1.134
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.9073.776+6.131
TTM9.0804.034+5.046
YOY8.1684.978+3.190
5Y8.6965.984+2.712
10Y7.5626.360+1.202
1.3.2. Quick Ratio

Measures if Galapagos N.V. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Galapagos N.V. to the¬†Biotechnology industry mean.
  • A Quick Ratio of 9.26¬†means the company can pay off €9.26 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Galapagos N.V.:

  • The MRQ is 9.260. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.864. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.260TTM14.864-5.604
TTM14.864YOY14.914-0.051
TTM14.8645Y13.642+1.222
5Y13.64210Y9.788+3.854
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.2603.198+6.062
TTM14.8643.631+11.233
YOY14.9144.843+10.071
5Y13.6425.825+7.817
10Y9.7886.378+3.410

1.4. Solvency of Galapagos N.V..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Galapagos N.V. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Galapagos N.V. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.34¬†means that Galapagos N.V. assets are¬†financed with 33.6% credit (debt) and the remaining percentage (100% - 33.6%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Galapagos N.V.:

  • The MRQ is 0.336. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.384. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.336TTM0.384-0.047
TTM0.384YOY0.462-0.078
TTM0.3845Y0.463-0.079
5Y0.46310Y0.347+0.116
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3360.336+0.000
TTM0.3840.346+0.038
YOY0.4620.284+0.178
5Y0.4630.367+0.096
10Y0.3470.376-0.029
1.4.2. Debt to Equity Ratio

Measures if Galapagos N.V. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Galapagos N.V. to the¬†Biotechnology industry mean.
  • A Debt to Equity ratio of 50.7% means that company has €0.51 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Galapagos N.V.:

  • The MRQ is 0.507. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.628. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.507TTM0.628-0.122
TTM0.628YOY0.858-0.230
TTM0.6285Y0.903-0.275
5Y0.90310Y0.607+0.296
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5070.382+0.125
TTM0.6280.421+0.207
YOY0.8580.371+0.487
5Y0.9030.447+0.456
10Y0.6070.476+0.131

2. Market Valuation of Galapagos N.V.

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Galapagos N.V. generates.

  • Above 15 is considered overpriced but¬†always compare¬†Galapagos N.V. to the¬†Biotechnology industry mean.
  • A PE ratio of 5.40 means the investor is paying €5.40¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Galapagos N.V.:

  • The EOD is 4.346. Based on the earnings, the company is cheap. +2
  • The MRQ is 5.401. Based on the earnings, the company is cheap. +2
  • The TTM is 37.677. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.346MRQ5.401-1.055
MRQ5.401TTM37.677-32.275
TTM37.677YOY2.360+35.317
TTM37.6775Y10.151+27.526
5Y10.15110Y-7.618+17.770
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.346-2.473+6.819
MRQ5.401-2.865+8.266
TTM37.677-2.837+40.514
YOY2.360-3.461+5.821
5Y10.151-6.135+16.286
10Y-7.618-6.468-1.150
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Galapagos N.V.:

  • The EOD is -3.047. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.787. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.271. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.047MRQ-3.787+0.740
MRQ-3.787TTM-5.271+1.485
TTM-5.271YOY-5.242-0.029
TTM-5.2715Y-10.565+5.294
5Y-10.56510Y-22.619+12.054
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.047-3.046-0.001
MRQ-3.787-3.513-0.274
TTM-5.271-3.609-1.662
YOY-5.242-4.805-0.437
5Y-10.565-7.882-2.683
10Y-22.619-8.502-14.117
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Galapagos N.V. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Biotechnology industry mean).
  • A PB ratio of 0.67 means the investor is paying €0.67¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Galapagos N.V.:

  • The EOD is 0.542. Based on the equity, the company is cheap. +2
  • The MRQ is 0.673. Based on the equity, the company is cheap. +2
  • The TTM is 0.829. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.542MRQ0.673-0.132
MRQ0.673TTM0.829-0.156
TTM0.829YOY1.096-0.267
TTM0.8295Y2.123-1.294
5Y2.12310Y3.817-1.695
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5422.012-1.470
MRQ0.6732.185-1.512
TTM0.8292.227-1.398
YOY1.0962.447-1.351
5Y2.1233.726-1.603
10Y3.8174.199-0.382
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Galapagos N.V. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.5091.253+20%-0.213+114%1.304+16%1.013+49%
Book Value Per Share--43.93241.337+6%39.561+11%39.426+11%25.117+75%
Current Ratio--9.9079.080+9%8.168+21%8.696+14%7.562+31%
Debt To Asset Ratio--0.3360.384-12%0.462-27%0.463-27%0.347-3%
Debt To Equity Ratio--0.5070.628-19%0.858-41%0.903-44%0.607-17%
Dividend Per Share----0%-0%-0%-0%
Eps--1.3691.057+29%-0.688+150%-0.044+103%-0.128+109%
Free Cash Flow Per Share---1.953-1.725-12%-2.144+10%0.814-340%0.299-754%
Free Cash Flow To Equity Per Share---1.971-1.748-11%-2.150+9%1.834-207%1.332-248%
Gross Profit Margin--1.000-0.228+123%1.119-11%0.820+22%0.889+12%
Intrinsic Value_10Y_max--9.758--------
Intrinsic Value_10Y_min---98.880--------
Intrinsic Value_1Y_max--1.164--------
Intrinsic Value_1Y_min---8.120--------
Intrinsic Value_3Y_max--3.356--------
Intrinsic Value_3Y_min---26.092--------
Intrinsic Value_5Y_max--5.377--------
Intrinsic Value_5Y_min---45.781--------
Market Cap1568350980.000-24%1949236218.0002248244309.250-13%2860593111.000-32%5242302471.766-63%4537216501.171-57%
Net Profit Margin--1.4450.235+514%-0.507+135%-0.316+122%-0.692+148%
Operating Margin---0.002-100%-0.5250%-0.3480%-0.8540%
Operating Ratio--1.5711.024+54%1.525+3%1.631-4%2.892-46%
Pb Ratio0.542-24%0.6730.829-19%1.096-39%2.123-68%3.817-82%
Pe Ratio4.346-24%5.40137.677-86%2.360+129%10.151-47%-7.618+241%
Price Per Share23.800-24%29.58034.118-13%43.410-32%79.144-63%68.648-57%
Price To Free Cash Flow Ratio-3.047+20%-3.787-5.271+39%-5.242+38%-10.565+179%-22.619+497%
Price To Total Gains Ratio15.772-24%19.60254.477-64%60.850-68%3751.641-99%2055.868-99%
Quick Ratio--9.26014.864-38%14.914-38%13.642-32%9.788-5%
Return On Assets--0.0210.016+30%-0.010+146%-0.002+110%-0.013+161%
Return On Equity--0.0310.025+25%-0.018+158%-0.003+111%-0.016+151%
Total Gains Per Share--1.5091.253+20%-0.213+114%1.304+16%1.013+49%
Usd Book Value--3100264067.2002917153553.450+6%2791803905.275+11%2792172455.510+11%1777453315.225+74%
Usd Book Value Change Per Share--1.6161.342+20%-0.228+114%1.397+16%1.085+49%
Usd Book Value Per Share--47.04744.268+6%42.366+11%42.221+11%26.898+75%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--1.4661.132+29%-0.737+150%-0.047+103%-0.137+109%
Usd Free Cash Flow---137820546.400-121757849.575-12%-151267034.525+10%57086841.115-341%20347796.085-777%
Usd Free Cash Flow Per Share---2.091-1.848-12%-2.296+10%0.872-340%0.320-754%
Usd Free Cash Flow To Equity Per Share---2.110-1.872-11%-2.302+9%1.964-207%1.426-248%
Usd Market Cap1679547064.482-24%2087437065.8562407644830.776-13%3063409162.570-32%5613981717.014-63%4858905151.103-57%
Usd Price Per Share25.487-24%31.67736.536-13%46.488-32%84.755-63%73.516-57%
Usd Profit--96616598.00074617634.750+29%-48585126.650+150%-6759574.345+107%-10894078.293+111%
Usd Revenue--66858428.80033007279.800+103%146659755.000-54%138267754.240-52%87191526.783-23%
Usd Total Gains Per Share--1.6161.342+20%-0.228+114%1.397+16%1.085+49%
 EOD+3 -5MRQTTM+21 -13YOY+23 -105Y+21 -1210Y+20 -13

3.2. Fundamental Score

Let's check the fundamental score of Galapagos N.V. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-154.346
Price to Book Ratio (EOD)Between0-10.542
Net Profit Margin (MRQ)Greater than01.445
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than19.260
Current Ratio (MRQ)Greater than19.907
Debt to Asset Ratio (MRQ)Less than10.336
Debt to Equity Ratio (MRQ)Less than10.507
Return on Equity (MRQ)Greater than0.150.031
Return on Assets (MRQ)Greater than0.050.021
Total7/10 (70.0%)

3.3. Technical Score

Let's check the technical score of Galapagos N.V. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5023.250
Ma 20Greater thanMa 5025.176
Ma 50Greater thanMa 10026.552
Ma 100Greater thanMa 20029.926
OpenGreater thanClose23.840
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets4,361,379
Total Liabilities1,466,371
Total Stockholder Equity2,895,008
 As reported
Total Liabilities 1,466,371
Total Stockholder Equity+ 2,895,008
Total Assets = 4,361,379

Assets

Total Assets4,361,379
Total Current Assets3,786,470
Long-term Assets574,909
Total Current Assets
Cash And Cash Equivalents 73,372
Short-term Investments 3,484,560
Net Receivables 54,611
Inventory 80,558
Other Current Assets 15,711
Total Current Assets  (as reported)3,786,470
Total Current Assets  (calculated)3,708,812
+/- 77,658
Long-term Assets
Property Plant Equipment 125,059
Goodwill 69,715
Intangible Assets 125,998
Long-term Assets Other 65,516
Long-term Assets  (as reported)574,909
Long-term Assets  (calculated)386,288
+/- 188,621

Liabilities & Shareholders' Equity

Total Current Liabilities382,214
Long-term Liabilities1,084,157
Total Stockholder Equity2,895,008
Total Current Liabilities
Accounts payable 145,551
Total Current Liabilities  (as reported)382,214
Total Current Liabilities  (calculated)145,551
+/- 236,663
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt7,977
Long-term Liabilities Other 42,887
Long-term Liabilities  (as reported)1,084,157
Long-term Liabilities  (calculated)50,864
+/- 1,033,293
Total Stockholder Equity
Total Stockholder Equity (as reported)2,895,008
Total Stockholder Equity (calculated)0
+/- 2,895,008
Other
Capital Stock293,937
Common Stock Shares Outstanding 65,897
Net Invested Capital 2,895,008
Net Working Capital 3,404,256



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-31
> Total Assets 
15,613
32,890
32,890
0
81,563
74,389
74,389
156,261
167,646
147,762
147,762
148,724
148,724
119,905
119,905
118,824
118,824
106,216
106,216
143,709
143,709
139,736
139,736
193,961
193,961
152,989
152,989
161,055
161,055
243,337
243,338
235,329
235,329
276,228
276,228
287,374
287,374
304,980
304,980
0
270,467
0
488,263
461,048
442,514
1,079,287
1,066,524
1,043,092
1,083,338
1,072,814
1,368,355
1,331,373
1,286,274
1,229,864
1,204,348
1,485,551
1,439,496
1,400,200
1,357,848
5,851,752
6,068,609
5,992,406
5,851,564
5,721,087
5,717,731
5,615,059
5,430,617
5,331,987
5,193,160
5,100,315
5,040,085
4,972,070
4,734,351
4,632,172
4,522,340
4,451,336
4,357,396
4,361,379
4,361,3794,357,3964,451,3364,522,3404,632,1724,734,3514,972,0705,040,0855,100,3155,193,1605,331,9875,430,6175,615,0595,717,7315,721,0875,851,5645,992,4066,068,6095,851,7521,357,8481,400,2001,439,4961,485,5511,204,3481,229,8641,286,2741,331,3731,368,3551,072,8141,083,3381,043,0921,066,5241,079,287442,514461,048488,2630270,4670304,980304,980287,374287,374276,228276,228235,329235,329243,338243,337161,055161,055152,989152,989193,961193,961139,736139,736143,709143,709106,216106,216118,824118,824119,905119,905148,724148,724147,762147,762167,646156,26174,38974,38981,563032,89032,89015,613
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
59,849
0
44,623
0
84,686
0
58,251
0
109,223
0
67,403
0
65,562
0
143,735
0
132,727
0
168,039
0
176,653
0
254,894
0
213,603
0
422,245
397,561
374,470
1,007,664
992,267
962,967
1,007,232
992,122
1,284,957
1,243,839
1,197,647
1,135,735
1,107,881
1,390,400
1,328,851
1,259,244
1,208,604
5,651,013
5,865,927
5,780,264
5,622,005
5,463,769
5,369,347
5,310,922
5,129,494
5,015,997
4,861,854
4,750,700
4,533,192
4,462,397
4,236,850
4,155,294
4,032,147
3,956,092
3,861,589
3,786,470
3,786,4703,861,5893,956,0924,032,1474,155,2944,236,8504,462,3974,533,1924,750,7004,861,8545,015,9975,129,4945,310,9225,369,3475,463,7695,622,0055,780,2645,865,9275,651,0131,208,6041,259,2441,328,8511,390,4001,107,8811,135,7351,197,6471,243,8391,284,957992,1221,007,232962,967992,2671,007,664374,470397,561422,2450213,6030254,8940176,6530168,0390132,7270143,735065,562067,4030109,223058,251084,686044,623059,8490000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,316
0
18,745
0
47,391
0
27,165
0
40,397
0
49,845
0
32,555
0
122,613
0
94,647
0
136,709
0
141,481
0
231,531
0
187,712
0
397,477
366,545
340,314
978,334
960,481
930,807
973,241
953,385
1,262,061
1,218,856
1,151,211
1,108,186
1,066,766
1,343,668
1,290,796
1,222,901
1,147,923
5,599,787
1,861,616
2,743,573
2,384,220
2,087,797
2,135,187
2,553,950
2,642,639
2,834,378
2,233,368
1,254,279
972,796
675,519
508,117
124,135
98,024
159,375
166,803
73,372
73,372166,803159,37598,024124,135508,117675,519972,7961,254,2792,233,3682,834,3782,642,6392,553,9502,135,1872,087,7972,384,2202,743,5731,861,6165,599,7871,147,9231,222,9011,290,7961,343,6681,066,7661,108,1861,151,2111,218,8561,262,061953,385973,241930,807960,481978,334340,314366,545397,4770187,7120231,5310141,4810136,709094,6470122,613032,555049,845040,397027,165047,391018,745027,3160000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,919,216
2,978,805
3,182,276
3,220,805
3,026,278
2,560,743
2,363,969
2,039,787
2,469,809
3,389,098
3,456,184
3,686,557
3,585,945
3,865,915
3,776,913
3,652,333
3,517,698
3,484,560
3,484,5603,517,6983,652,3333,776,9133,865,9153,585,9453,686,5573,456,1843,389,0982,469,8092,039,7872,363,9692,560,7433,026,2783,220,8053,182,2762,978,8053,919,216000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
2,169
2,120
2,120
0
9,786
5,729
5,729
24,846
24,847
24,702
24,702
26,500
23,581
19,761
19,761
26,427
26,616
20,131
20,131
32,489
31,984
26,173
26,173
63,546
63,484
14,304
14,304
28,857
30,010
16,083
16,083
33,242
33,242
26,540
26,540
31,979
31,979
20,061
20,061
0
13,795
0
11,801
19,163
16,057
15,075
17,625
18,127
23,478
26,164
15,642
17,740
41,788
20,086
33,762
37,006
33,533
26,992
53,711
42,388
80,109
49,180
45,190
139,299
173,400
180,347
113,600
126,802
128,601
78,521
64,058
54,374
77,344
67,569
67,576
73,044
65,655
54,611
54,61165,65573,04467,57667,56977,34454,37464,05878,521128,601126,802113,600180,347173,400139,29945,19049,18080,10942,38853,71126,99233,53337,00633,76220,08641,78817,74015,64226,16423,47818,12717,62515,07516,05719,16311,801013,795020,06120,06131,97931,97926,54026,54033,24233,24216,08316,08330,01028,85714,30414,30463,48463,54626,17326,17331,98432,48920,13120,13126,61626,42719,76119,76123,58126,50024,70224,70224,84724,8465,7295,7299,78602,1202,1202,169
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
2,919
0
0
2,532
2,343
1,604
1,604
2,990
3,495
3,139
3,139
3,843
3,905
2,193
2,193
3,647
2,495
4,522
4,522
4,634
4,634
4,520
4,520
2,944
5,091
3,005
3,005
0
11,815
0
5,751
4,653
-1
5,642
6,981
6,848
1
8,215
6,936
6,939
1
7,170
7,086
7,432
4,246
9,351
6,970
8,838
4,731
8,706
10,319
15,868
34,127
15,882
9,286
15,030
-1
10,404
13,146
20,437
2
27,897
40,766
15,735
37,455
15,711
15,71137,45515,73540,76627,897220,43713,14610,404-115,0309,28615,88234,12715,86810,3198,7064,7318,8386,9709,3514,2467,4327,0867,17016,9396,9368,21516,8486,9815,642-14,6535,751011,81503,0053,0055,0912,9444,5204,5204,6344,6344,5224,5222,4953,6472,1932,1933,9053,8433,1393,1393,4952,9901,6041,6042,3432,532002,919000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
58,975
0
61,593
0
59,023
0
81,485
0
84,738
0
85,586
0
95,493
0
99,601
0
102,602
0
108,189
0
110,721
0
50,086
0
56,864
0
66,018
63,487
68,044
71,624
74,257
80,127
76,107
80,692
83,398
0
88,627
94,129
96,467
95,151
110,645
140,956
149,244
200,739
202,682
212,142
229,559
257,318
348,384
304,136
301,123
315,990
331,306
349,615
506,893
509,673
497,501
476,877
490,193
495,244
495,807
574,909
574,909495,807495,244490,193476,877497,501509,673506,893349,615331,306315,990301,123304,136348,384257,318229,559212,142202,682200,739149,244140,956110,64595,15196,46794,12988,627083,39880,69276,10780,12774,25771,62468,04463,48766,018056,864050,0860110,7210108,1890102,602099,601095,493085,586084,738081,485059,023061,593058,9750000000000000000
       Property Plant Equipment 
2,625
2,669
2,669
0
9,399
9,939
9,939
25,540
25,965
26,013
26,013
22,914
22,914
21,135
21,135
20,293
20,293
20,542
20,542
19,285
19,285
20,473
20,473
23,886
23,886
20,310
20,310
19,524
19,523
19,253
19,253
18,099
18,099
17,273
17,273
19,525
19,525
10,761
10,761
0
10,091
0
11,178
12,577
13,783
14,110
15,091
15,032
14,959
15,064
15,506
15,279
16,692
16,971
17,854
18,113
23,138
49,542
51,180
61,883
66,054
66,979
73,786
94,661
103,379
111,294
111,900
123,637
137,513
145,896
148,866
150,394
154,253
134,888
134,728
136,803
126,321
125,059
125,059126,321136,803134,728134,888154,253150,394148,866145,896137,513123,637111,900111,294103,37994,66173,78666,97966,05461,88351,18049,54223,13818,11317,85416,97116,69215,27915,50615,06414,95915,03215,09114,11013,78312,57711,178010,091010,76110,76119,52519,52517,27317,27318,09918,09919,25319,25319,52319,52420,31020,31023,88623,88620,47320,47319,28519,28520,54220,54220,29320,29321,13521,13522,91422,91426,01326,01325,96525,5409,9399,9399,39902,6692,6692,625
       Goodwill 
0
0
0
0
29,481
29,112
29,112
32,996
35,560
35,948
35,948
33,952
33,952
33,952
33,952
33,751
33,751
33,751
33,751
33,751
33,751
42,710
42,710
42,380
42,380
38,880
38,880
38,880
38,880
38,314
38,314
37,667
37,667
39,240
39,240
39,239
39,239
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
174,288
174,994
69,813
69,672
69,678
69,863
69,557
69,715
69,71569,55769,86369,67869,67269,813174,994174,28800000000000000000000000000000000039,23939,23939,24039,24037,66737,66738,31438,31438,88038,88038,88038,88042,38042,38042,71042,71033,75133,75133,75133,75133,75133,75133,95233,95233,95233,95235,94835,94835,56032,99629,11229,11229,4810000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
46,524
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,754
0
0
0
6,000
0
0
0
11,275
0
0
0
8,951
0
0
0
0
0
0
0
0
0
0
0
13,575
0
013,575000000000008,95100011,2750006,0000001,754000000000000000000046,52400000000000000000000000000000000
       Intangible Assets 
447
422
422
0
34,350
33,690
33,690
42,445
53,404
53,164
53,164
40,042
40,042
40,019
40,019
37,910
4,159
37,960
4,209
37,231
3,480
58,248
15,538
55,914
13,534
50,068
11,188
49,494
10,614
48,135
9,821
47,091
9,426
47,768
8,528
47,071
7,833
1,862
1,862
0
2,016
0
1,575
1,517
1,552
1,382
1,226
1,150
1,025
963
859
747
2,498
2,555
1,403
2,058
3,631
6,497
7,191
23,492
24,925
33,856
39,254
41,114
67,566
65,738
63,072
59,623
60,103
0
32,346
38,493
146,353
140,914
136,470
132,313
127,906
125,998
125,998127,906132,313136,470140,914146,35338,49332,346060,10359,62363,07265,73867,56641,11439,25433,85624,92523,4927,1916,4973,6312,0581,4032,5552,4987478599631,0251,1501,2261,3821,5521,5171,57502,01601,8621,8627,83347,0718,52847,7689,42647,0919,82148,13510,61449,49411,18850,06813,53455,91415,53858,2483,48037,2314,20937,9604,15937,91040,01940,01940,04240,04253,16453,16453,40442,44533,69033,69034,3500422422447
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
772
0
52
0
807
0
1,064
0
1,280
0
14,041
0
24,310
0
28,676
0
417
0
41,252
0
39,346
0
1
0
520
0
865
1,594
1,599
1,603
1,692
4,261
3,978
4,015
3,834
0
3,458
3,339
3,663
3,700
7,919
6,377
5,713
5,993
96,223
13,945
9,522
8,647
164,013
4,465
4,422
4,455
2,472
140,531
8,388
7,832
1,209
5,702
17,927
16,912
157,322
65,516
65,516157,32216,91217,9275,7021,2097,8328,388140,5312,4724,4554,4224,465164,0138,6479,52213,94596,2235,9935,7136,3777,9193,7003,6633,3393,45803,8344,0153,9784,2611,6921,6031,5991,594865052001039,346041,2520417028,676024,310014,04101,28001,064080705207720000000000000000
> Total Liabilities 
5,246
5,044
5,044
0
20,427
18,591
18,591
46,719
58,104
43,574
43,574
50,098
50,098
31,674
31,674
34,500
34,500
26,975
26,975
34,832
34,832
36,555
36,555
45,455
45,454
34,697
34,697
42,679
42,679
130,997
130,998
116,882
116,882
108,216
108,216
120,237
120,237
79,965
79,965
0
64,332
0
44,808
42,258
77,515
350,742
336,724
334,271
324,637
324,664
299,329
294,441
274,291
330,519
318,689
297,329
225,247
224,445
214,481
3,316,471
3,192,951
3,152,365
3,078,301
3,009,004
3,047,376
2,913,597
2,767,144
2,714,604
2,549,798
2,453,726
2,393,187
2,281,719
2,208,325
2,067,568
1,938,392
1,829,776
1,561,830
1,466,371
1,466,3711,561,8301,829,7761,938,3922,067,5682,208,3252,281,7192,393,1872,453,7262,549,7982,714,6042,767,1442,913,5973,047,3763,009,0043,078,3013,152,3653,192,9513,316,471214,481224,445225,247297,329318,689330,519274,291294,441299,329324,664324,637334,271336,724350,74277,51542,25844,808064,332079,96579,965120,237120,237108,216108,216116,882116,882130,998130,99742,67942,67934,69734,69745,45445,45536,55536,55534,83234,83226,97526,97534,50034,50031,67431,67450,09850,09843,57443,57458,10446,71918,59118,59120,42705,0445,0445,246
   > Total Current Liabilities 
3,608
3,688
3,688
0
14,065
12,305
12,305
29,655
29,278
22,704
22,704
43,361
43,361
25,532
25,532
29,751
29,751
22,787
22,787
31,344
31,344
28,053
28,053
38,223
38,223
27,818
27,818
35,360
35,360
124,367
124,367
109,014
109,014
99,294
99,294
112,559
112,559
75,977
75,977
0
60,356
0
40,299
37,251
72,412
104,736
111,549
129,826
103,791
127,984
130,678
154,531
171,699
223,631
246,586
269,102
219,905
199,450
188,712
631,300
571,793
622,626
618,538
601,744
635,274
605,362
576,985
575,494
566,474
562,896
550,725
532,207
522,538
522,904
475,073
444,036
428,223
382,214
382,214428,223444,036475,073522,904522,538532,207550,725562,896566,474575,494576,985605,362635,274601,744618,538622,626571,793631,300188,712199,450219,905269,102246,586223,631171,699154,531130,678127,984103,791129,826111,549104,73672,41237,25140,299060,356075,97775,977112,559112,55999,29499,294109,014109,014124,367124,36735,36035,36027,81827,81838,22338,22328,05328,05331,34431,34422,78722,78729,75129,75125,53225,53243,36143,36122,70422,70429,27829,65512,30512,30514,06503,6883,6883,608
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
546
0
255
0
520
0
419
0
378
0
396
0
425
0
406
0
240
0
246
0
226
0
114
0
52
0
51
51
52
52
53
53
54
50
37
23
9
1,805
862
855
2,065
4,580
5,141
5,251
5,826
6,210
6,872
7,116
6,401
6,475
6,480
7,262
7,204
7,065
7,179
6,926
7,209
5,782
6,210
5,678
4,652
0
04,6525,6786,2105,7827,2096,9267,1797,0657,2047,2626,4806,4756,4017,1166,8726,2105,8265,2515,1414,5802,0658558621,8059233750545353525251510520114022602460240040604250396037804190520025505460000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
316
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
63
50
37
23
9
0
0
0
0
4,580
5,141
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000005,1414,580000092337506300000000000000031600000000000000000000000000000000
       Accounts payable 
2,766
3,042
3,042
0
9,568
9,711
9,711
11,805
25,431
18,631
18,631
13,293
13,293
23,588
23,588
13,425
13,425
11,850
11,850
15,130
15,130
12,556
12,556
22,012
22,012
16,107
16,107
18,068
18,068
15,739
15,739
22,093
22,093
20,449
20,449
29,365
29,365
23,047
23,047
0
30,007
0
32,823
32,775
29,113
24,223
22,673
27,749
31,209
46,964
36,686
48,437
47,122
55,657
69,141
80,721
68,038
69,880
86,216
156,254
142,510
169,477
179,432
157,259
171,316
161,867
151,721
145,260
134,304
134,668
160,746
154,745
133,298
155,949
131,074
121,129
134,653
145,551
145,551134,653121,129131,074155,949133,298154,745160,746134,668134,304145,260151,721161,867171,316157,259179,432169,477142,510156,25486,21669,88068,03880,72169,14155,65747,12248,43736,68646,96431,20927,74922,67324,22329,11332,77532,823030,007023,04723,04729,36529,36520,44920,44922,09322,09315,73915,73918,06818,06816,10716,10722,01222,01212,55612,55615,13015,13011,85011,85013,42513,42523,58823,58813,29313,29318,63118,63125,43111,8059,7119,7119,56803,0423,0422,766
       Other Current Liabilities 
736
536
536
0
1,530
594
594
14,678
675
383
383
27,447
27,447
850
850
15,796
15,724
10,682
2,014
15,694
15,650
15,078
15,078
15,833
15,789
11,315
11,271
16,867
15,858
108,222
107,455
86,681
3,073
78,599
3,082
82,968
3,989
52,816
52,344
0
3,271
0
3,255
3,146
3,441
3,195
2,862
2,851
1,701
1,944
2,062
106,071
2,024
1
861
867
1
1,168
1,030
1,031
9,159
27,868
28,578
15,394
14,398
2,277
713
593
5,100
3,039
724
873
16,400
9,857
7,154
1,764
32,648
0
032,6481,7647,1549,85716,4008737243,0395,1005937132,27714,39815,39428,57827,8689,1591,0311,0301,168186786112,024106,0712,0621,9441,7012,8512,8623,1953,4413,1463,25503,271052,34452,8163,98982,9683,08278,5993,07386,681107,455108,22215,85816,86711,27111,31515,78915,83315,07815,07815,65015,6942,01410,68215,72415,79685085027,44727,44738338367514,6785945941,5300536536736
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,749
0
4,188
0
3,488
0
8,502
0
7,231
0
6,879
0
7,319
0
6,631
0
7,868
0
8,922
0
7,678
0
3,988
0
3,976
0
4,509
5,007
5,103
246,006
225,175
204,445
220,846
196,680
168,651
0
102,592
106,888
72,103
28,227
5,342
24,995
25,769
2,685,171
2,621,158
2,529,739
2,459,763
2,407,260
2,412,102
2,308,235
2,190,159
2,139,110
1,983,324
1,890,830
1,842,462
1,749,512
1,685,787
1,544,664
1,463,319
1,385,740
1,133,607
1,084,157
1,084,1571,133,6071,385,7401,463,3191,544,6641,685,7871,749,5121,842,4621,890,8301,983,3242,139,1102,190,1592,308,2352,412,1022,407,2602,459,7632,529,7392,621,1582,685,17125,76924,9955,34228,22772,103106,888102,5920168,651196,680220,846204,445225,175246,0065,1035,0074,50903,97603,98807,67808,92207,86806,63107,31906,87907,23108,50203,48804,18804,7490000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,457
19,661
19,558
18,856
20,384
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000020,38418,85619,55819,66120,4570000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
214
63
63
11,875
23,637
18,110
18,110
4,698
4,698
4,252
4,252
3,392
3,392
2,531
2,531
1,960
1,960
2,704
2,704
3,672
3,672
3,813
3,813
4,465
4,465
4,381
4,381
5,079
5,079
6,074
6,074
5,319
5,319
3,848
3,848
0
3,860
0
4,420
4,931
5,040
245,956
225,138
204,423
220,837
196,680
168,651
139,910
102,592
106,888
72,103
28,227
5,342
4,586
5,312
2,665,510
2,601,600
2,510,883
2,439,379
2,385,310
2,389,066
2,286,059
2,168,730
2,119,982
1,963,669
1,872,541
1,825,587
1,733,753
1,671,095
0
0
0
0
0
000001,671,0951,733,7531,825,5871,872,5411,963,6692,119,9822,168,7302,286,0592,389,0662,385,3102,439,3792,510,8832,601,6002,665,5105,3124,5865,34228,22772,103106,888102,592139,910168,651196,680220,837204,423225,138245,9565,0404,9314,42003,86003,8483,8485,3195,3196,0746,0745,0795,0794,3814,3814,4654,4653,8133,8133,6723,6722,7042,7041,9601,9602,5312,5313,3923,3924,2524,2524,6984,69818,11018,11023,63711,87563632140000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,460
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,872
0
0
0
13,334
0
0
0
11,796
0
0
0
0
0
0
0
0
0
00000000011,79600013,33400014,8720000000000000000000000000003,46000000000000000000000000000000000
> Total Stockholder Equity
10,367
27,846
27,846
27,846
61,136
55,798
55,798
109,542
109,542
104,188
104,188
98,626
98,626
88,231
88,231
84,324
84,324
79,241
79,241
108,877
108,877
103,181
103,181
148,506
148,507
118,292
118,292
118,376
118,376
112,340
112,340
118,447
118,447
168,012
168,012
167,137
167,136
225,015
225,015
0
206,135
206,135
443,455
418,790
364,999
728,545
729,800
708,821
758,701
748,150
1,069,026
1,036,932
1,011,984
899,345
885,659
1,188,222
1,214,249
1,175,755
1,143,367
2,535,281
2,875,658
2,840,041
2,773,263
2,712,083
2,670,355
2,701,462
2,663,473
2,617,383
2,643,362
2,646,589
2,646,898
2,690,351
2,526,026
2,564,604
2,583,948
2,621,560
2,795,566
2,895,008
2,895,0082,795,5662,621,5602,583,9482,564,6042,526,0262,690,3512,646,8982,646,5892,643,3622,617,3832,663,4732,701,4622,670,3552,712,0832,773,2632,840,0412,875,6582,535,2811,143,3671,175,7551,214,2491,188,222885,659899,3451,011,9841,036,9321,069,026748,150758,701708,821729,800728,545364,999418,790443,455206,135206,1350225,015225,015167,136167,137168,012168,012118,447118,447112,340112,340118,376118,376118,292118,292148,507148,506103,181103,181108,877108,87779,24179,24184,32484,32488,23188,23198,62698,626104,188104,188109,542109,54255,79855,79861,13627,84627,84627,84610,367
   Retained Earnings -133,080-228,274-403,242-440,792-459,821-496,689-326,905-367,381-366,119-367,205-391,311-345,101-306,881-334,701-297,098-235,224-150,597-109,223-3,907-376,518-340,020-297,779-321,495-343,796-328,620-211,441-186,432-154,553-122,854-112,272-162,048-140,845-139,465-177,317-122,634-97,1420-63,9440-42,6970-100,1070-99,6350-94,7700-101,5990-91,1400-90,1090-60,0790-76,2730-66,8680-78,1170-72,4920000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
45,961
0
-1,947
0
52,875
0
55,073
0
71,463
0
70,950
0
72,056
0
3,199
0
994
0
844
0
217
0
-1,723
0
-1,377
0
-416
-786
-485
-867
-1,057
-1,423
-2,090
-2,059
-2,215
0
-3,014
-2,398
-2,245
-2,239
-2,292
-2,025
-2,240
-2,002
-5,984
-5,582
-5,646
-7,356
-14,096
-13,067
-13,162
-13,194
-11,899
-11,918
-11,806
-11,906
-6,446
-6,505
-6,190
-6,128
-7,091
0
0-7,091-6,128-6,190-6,505-6,446-11,906-11,806-11,918-11,899-13,194-13,162-13,067-14,096-7,356-5,646-5,582-5,984-2,002-2,240-2,025-2,292-2,239-2,245-2,398-3,0140-2,215-2,059-2,090-1,423-1,057-867-485-786-4160-1,3770-1,72302170844099403,199072,056070,950071,463055,073052,8750-1,947045,9610000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,283,650
2,268,585
2,703,583
2,708,114
2,723,671
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000002,723,6712,708,1142,703,5832,268,5851,283,6500000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in EUR. All numbers in thousands.